UPDATED: #ASCO22: Enhertu blows chemotherapy out of the water, redefining breast cancer subgroups along the way
CHICAGO — When Camille Hertzka found out the results of a study showing breast cancer drug Enhertu cut disease progression or death by about half, the AstraZeneca VP immediately thought of the potential for patients, some of whom are friends.
Given her position leading US medical affairs for AZ’s oncology unit, Hertzka of course couldn’t tell her friend with HER2-low breast cancer the results of the study, but that friend was still top of mind as the Big Pharma geared up to present the landmark results at the annual ASCO meeting on Sunday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.